The news: Hims & Hers is launching Peptides+, a branded platform offering five compounded peptide and wellness treatments in the US, including sermorelin, NAD+, glutathione, vitamin B12, and L-carnitine. Providers will prescribe treatments after a review, with prices starting at $99 per month, per Hims & Hers.
Hims’ move comes a day after Noom introduced OpenRx, a peptide and preventive health platform also offering clinician-prescribed compounds including sermorelin and NAD+ treatments. Both companies say they may eventually add BPC-157 and TB-500, two peptides covered by a recent HHS policy change that allows certain compounding while federal rulemaking is ongoing.
Why it matters: Hims and Noom are bringing peptide treatments associated with online wellness trends into well-known telehealth platforms. The launches could make these treatments appear more mainstream and credible to consumers, even though the compounded drugs have not undergone FDA review for safety and effectiveness.
The new platforms tap into a market where consumers are already using peptides and seeking information online. Some 48% of doctors report patients disclosing use of non-FDA-approved peptides in the past year, per a May Sermo survey of 507 US physicians. And 84% of those physicians say patients cite social media, podcasts, influencers, or online forums as sources of peptide information.
The platforms’ access to licensed healthcare professionals could appeal to consumers who want medical guidance before trying peptides. Similar shares of Gen Zers and millennials (27%) and Gen Xers and older consumers (26%) would consider peptides only with a doctor's prescription. But younger consumers were twice as likely as older consumers to consider them on a healthcare or wellness professional’s recommendation (32% vs. 16%), per The New Consumer's 2026 midyear trend report.
Implications for telehealth and healthcare marketers: Many patients learn about peptides online, and the FDA hasn’t reviewed the compounded versions for safety or effectiveness. In that market, clinical oversight could become part of the treatments’ perceived value. For telehealth marketers, established provider relationships and transparent prescribing practices can set their services apart from less familiar peptide sellers.
For healthcare marketers more broadly, the launches show how established brands can lend credibility to treatments with uncertain clinical evidence. That creates reputational risks, particularly if Hims and Noom expand into additional peptides under the recent HHS policy change. The challenge will be using brand credibility to build confidence in the care experience without overstating the evidence behind the treatments themselves.
This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.
You've read 0 of 2 free articles this month.
685 Third Avenue21st FloorNew York, NY 100171-800-405-0844
1-800-405-0844[email protected]